{
    "medicine_id": "238ef7cbfa32355996ad0275eebbbb2322abc975",
    "platform_id": "DB13968",
    "metadata": {
        "name": "Octaplas 11 5 g 200mL Solution",
        "composition": "11 5 g 200mL Plasma protein fraction human",
        "clinical_particulars": {
            "therapeutic_indications": "PPFh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy It is also used as a substitution therapy in emergency cases of factor deficiencies for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy PPFh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpura L2264 PPFh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cells L2261",
            "contraindications": {
                "disease": "Overdosage of PPFh can result in hypervolemia pulmonary edema and or cardiac failure L2264 Studies regarding the mutagenic potential effect in fertility and peri and post natal development genotoxic potential and carcinogenic properties demonstrate that PPFh is an inactive product L2266",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Preclinical studies were not performed as this product is exclusively human and any result in animals is not relevant This factor creates the need for having very regulated manufacturing processes From this control the presence of two contaminants have been noticed TNBP and Octoxynol The administration of this two contaminants in rodents showed a very rapid elimination of TNBP with a terminal half life of 20 min TNBP was never found in urine and only traces were located in feces In the case of octoxynol it was not detected in plasma urine or feces L2266 In humans the use of PPFh is been reported to consistently regularize the level of all blood factors In clinical trials was also observed a complete stop of abnormal bleeding L2266 The reported effect was sustained during 48 hours in the case of shock treatment L2261",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}